BIO-106
/ BiOneCure
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
April 06, 2022
BiOneCure Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for BIO-106, a Novel TROP2 ADC for the Treatment of Advanced Solid Tumors
(PRNewswire)
- "BiOneCure Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the IND for BIO-106, an antibody-drug conjugate (ADC) designed to target TROP-2 to treat a broad range of advanced solid tumors....The clinical study cleared by the FDA, known as StarBridge-1, is a Phase I/II, multicenter, open-label study to evaluate the safety, pharmacokinetics and preliminary anti-tumor activity of BIO-106 as monotherapy and in combination with pembrolizumab in patients with advanced cancers."
IND • Oncology • Solid Tumor
April 11, 2022
A Phase 1/2 Study in Patients With Advanced Cancers
(clinicaltrials.gov)
- P1/2 | N=332 | Recruiting | Sponsor: BiOneCure Therapeutics Inc.
Combination therapy • Monotherapy • New P1/2 trial • Oncology • Solid Tumor
1 to 2
Of
2
Go to page
1